Biotech companies attack NIH rules

Market entry and exit by biotech and device companies funded by venture capital.

Start-up companies in the biotechnology and medical device sectors are important sources of health care innovation. This paper describes the role of venture capital in supporting these companies and charts the growth in venture capital financial support. The paper then uses longitudinal data to describe market entry and exit by these companies. Similar factors are associated with entry and exit...

Competiveness and Innovation in High-tech Companies: an Application to the Italian Biotech and Aerospace Industries

Innovation activities are a critical factor in national and regional development. The innovative behaviour of companies is one of the main sources of competitiveness, business survival, economic growth and employment in a territory. It is therefore important to identify and understand the factors that determine innovation behaviour among enterprises. In line with...

Vital Factors behind the Strategic Alliances of the Biotech Companies in Taiwan

Biotechnology industry is well-known as a knowledge intensive industry and required relatively large financial support. As the demanding nature from both finance and knowledge/technology resources, biotech companies tend to strategically collaborate with others for product development and marketing. Therefore, a growing need of strategic alliance was observed in biopharmaceutical industry of Ta...

Recombinant DNA: NIH rules broken in insulin gene project.

Transient ischemic attack: the rules have changed.

Bob: If you thought you knew what a transient ischemic attack (TIA) is, and how to evaluate for it, think again. This scientific statement snuck past a lot of us and its implications are far-reaching. The guideline includes three game changers for all physicians: • It revises the definition of TIA • It recommends that magnetic resonance imaging (MRI) be performed within 24 hours in patients pre...